Aktis Oncology, Inc. (AKTS) earnings
Quarterly results of Aktis Oncology, Inc. as filed with the SEC: revenue, net income and earnings per share for each of the last 4 quarters, the latest results release and when the next one is expected.
Next earnings date
Aktis Oncology, Inc. was expected to report around October 20, 2026; nothing is on file with the SEC yet.
Latest quarter: Q2 FY2026
In Q2 FY2026 (ended June 30, 2026) Aktis Oncology, Inc. reported revenue of $3.4M and a net loss of $24.1M.
Diluted earnings per share were -$0.44.
Quarter by quarter
| Quarter | Revenue | vs year ago | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | $3.4M | - | -$24.1M | -$0.44 |
| Q1 FY2026 | $3.2M | - | -$18.3M | -$0.38 |
| Q2 FY2026 | $1.6M | - | -$18.1M | -$22.39 |
| Q1 FY2026 | $1.4M | - | -$15M | -$18.60 |
Results filings
- Quarterly report 10-Q
- Quarterly results 8-K
- Quarterly report 10-Q
- Quarterly results 8-K
- Quarterly results 8-K
- Annual report 10-K
When is Aktis Oncology, Inc.'s next earnings date?
Aktis Oncology, Inc. was expected to report around October 20, 2026; nothing is on file with the SEC yet.
What were Aktis Oncology, Inc.'s latest quarterly results?
For Q2 FY2026, which ended June 30, 2026, Aktis Oncology, Inc. reported revenue of $3.4M and a net loss of $24.1M. The figures come from its filing with the SEC.
Get an email when AKTS reports
Follow AKTS and we email you its next results the day they are filed, with the numbers explained.